SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

NCT07311408 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer (GC)
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SHR-1701+Rivoceranib + SHR-2554
DRUG: SHR-1701 + Rivoceranib

Sponsor

Jingdong Zhang